Weil Company’s Editas Medicine EDIT Stock Holding History

Weil Company’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-300	Closed	-$7K	–	177
2019 Q3	$7K	Buy	+300	New	+$7.43K	0.01%	310

Other funds holding EDIT

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Weil Company's EDIT Position: Q4 2019 in Review

Weil Company sold out of Editas Medicine (EDIT) in Q4 2019, closing a stake of 300 shares — an estimated $7K sold.

Weil Company first reported a position in EDIT in Q3 2019 and held it in 1 quarter. The position peaked at $7K in Q3 2019. 229 funds tracked by Wall St. Rank hold EDIT as of Q4 2019.

Weil Company reported no remaining Editas Medicine position as of Q4 2019 after selling out during the quarter.
Weil Company sold 300 Editas Medicine shares in Q4 2019, an estimated $7K.
Weil Company first reported a position in Editas Medicine in Q3 2019 and held it in 1 quarter.
Weil Company's Editas Medicine position peaked at $7K in Q3 2019.
229 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2019.

Based on Weil Company's 13F filing for Q4 2019, filed 13 Feb 2020.